724788-70-9

Usage

Uses

Used in Pharmaceutical Research and Development:
8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE is used as a building block for the design and synthesis of new drug molecules with potential therapeutic applications. Its structure and properties make it a valuable component in the creation of innovative drug candidates.
Used in Drug Synthesis:
8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE is used as a key intermediate in the synthesis of potential drug candidates. Its unique chemical structure and reactivity allow for the development of new compounds with improved pharmacological properties and therapeutic efficacy.
Used in Drug Discovery:
8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE is used as a tool in drug discovery efforts. Its chemical properties and reactivity enable researchers to explore new pathways and mechanisms for the treatment of various diseases and conditions.

InChI:InChI=1/C9H6BrFN2O/c1-14-7-3-2-6-9(13-7)8(10)5(11)4-12-6/h2-4H,1H3

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 724788-64-1 ethyl 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate 
• 724788-65-2 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylic acid 
• 724788-66-3 4-bromo-6-(methyloxy)-1,5-naphthyridin-3-amine 
• 1417551-48-4 t-butyl 4-bromo-6-methoxy-1,5-naphthyridine-3-yl-carbamate 
• 724788-63-0 ethyl 6-methoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1075259-77-6 3-fluoro-6-methoxy-1,5-naphthyridin-4-ol 
• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 53241-90-0 diethyl {[(6-methoxypyridin-3-yl)amino]methylidene}propanedioate 
• 53241-92-2 4-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic Acid Ethyl Ester 
• 724788-68-5 C₉H₆BrN₄O⁽¹⁺⁾ 
• 25063-69-8 5-[[(6-methoxypyridin-3-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1075259-74-3 2-(1-ethoxyethylene)-6-methoxy-3-nitropyridine 
• 1075259-75-4 2-fluoro-1-(6-methoxy-3-nitropyridin-2-yl)ethanone 

Downstream Products

• 1001322-69-5 8-allyl-7-fluoro-2-methoxy-1,5-naphthyridine 
• 1003944-32-8 7-fluoro-2-methoxy-1,5-naphthyridine 
• 881658-51-1 (E)-7-fluoro-2-methoxy-8-styryl-1,5-naphthyridine 
• 1072828-03-5 [1-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-piperidin-4-yl]-carbamic acid benzyl ester 
• 1072827-86-1 7-fluoro-2-methoxy-8-piperazin-1-yl-[1,5]naphthyridine 
• 59813-07-9 piperazine monohydrobromide 
• 1072827-26-9 [1-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-azetidin-3-yl]-carbamic acid benzyl ester 
• 1003944-35-1 8-bromo-2,7-dimethoxy-1,5-naphthyridine 
• 1072825-59-2 (R)-5-{[1-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-azetidin-3-ylamino]-methyl}-3-(3-fluoro-4-methyl-phenyl)-oxazolidin-2-one 
• 943025-77-2 [(4R/S)-3-fluoro-4-hydroxy-7-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-4-yl]methyl 4-methylbenzenesulfonate 
• 881658-52-2 1-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-2-phenylethane-1,2-diol 
• 1415415-01-8 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine 
• 1616409-89-2 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1616409-88-1 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 

Relevant academic research and scientific papers

1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition

The development of new therapies to treat methicillin-resistant Staphylococcus aureus (MRSA) is needed to counteract the significant threat that MRSA presents to human health. Novel inhibitors of DNA gyrase and topoisomerase IV (TopoIV) constitute one highly promising approach, but continued optimization is required to realize the full potential of this class of antibiotics. Herein, we report further studies on a series of dioxane-linked derivatives, demonstrating improved antistaphylococcal activity and reduced hERG inhibition. A subseries of analogues also possesses enhanced inhibition of the secondary target, TopoIV.

SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR

Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.

TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF

Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA, MDR P. aeruginosa, and other pathogens are also described.

BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit

A one-pot diazotation-fluorodediazoniation reaction and fluorine gas for the production of fluoronaphthyridines

Several synthetic routes to 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine (1) are presented, and their suitability for scale-up is discussed. The way of introducing the fluorine atom is crucial. Early routes start from commercially available fluorinated building blocks or employ F+ reagents like SelectFluor and delivered up to 70 kg of 7-fluoro-2-methoxy-1,5-naphthyridine (18). To prepare for larger scales, the focus turned to the use of HF or elemental fluorine, both one of the cheapest sources of fluorine. The first method, a one-pot diazotation-fluorodediazoniation with 6-methoxy-1,5- naphthyridin-3-amine (9) in HF gave the fluorinated naphthyridine 18 in high yield and purity without isolation of the unstable diazonium salt, the latter being a severe drawback of the related Balz-Schiemann protocol. The second method relies on the use of fluorine gas for a surprisingly selective ortho-fluorination of 6-methoxy-1,5-naphthyridin-4-ol (10).

PROCESS FOR MANUFACTURING NAPHTHYRIDINE DERIVATIVES

The invention relates to a new process suitable for manufacturing the compounds of formula I (I) wherein W is H, Br, CI or methyl, which are synthetic intermediates useful preparation of antibiotic compounds.

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases

We have identified a series of amino-piperidine antibacterials with a good broad spectrum potency. We report the investigation of various subunits in this series and advanced studies on compound 8. Compound 8 possesses good pharmacokinetics, broad spectrum antibacterial activity and demonstrates oral efficacy in a rat lung infection model.

NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS

Compounds of Formula (I) wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.